At a glance
ClinicalIndex Comparison RecordN/ACompleted· 218 enrolled
Drug / intervention
Aviva Expert blood glucose meter +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multi-centre Study With Diabetic Patients Randomized to 24 Weeks Treatment Supported by Either Accu-Chek® Aviva Expert Blood Glucose Meter With an Integrated Bolus Advisor or MDI Standard Therapy With Accu-Chek® Aviva Nano Meter (Without Bolus Advisor)
In Brief
A clinical study evaluating Aviva Expert blood glucose meter and Aviva Nano blood glucose meter for Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2. Completed, enrolled 218 participants across 33 sites in 2 countries.
Detailed Summary
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified conventional therapy (MDI/ICT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedOct 2011
Primary CompletionSep 2012
TodayJul 2026
First PostedOct 26, 2011
Enrollment StartOct 1, 2011
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.7 years ago
Interventions
Aviva Expert blood glucose meterdevice
Aviva Nano blood glucose meterdevice